Alison Grant


of International Health and Dean, Faculty of Infectious and Tropical Diseases

Room 301

Keppel Street
United Kingdom

+44 20 7927 2304

+44 20 7927 2739

I trained initially as a physician specialising in infectious and tropical diseases and HIV medicine, and continue to work in HIV medicine in London. I studied epidemiology at LSHTM with particular interests in care for people with HIV in developing countries.


Department of Clinical Research
Faculty of Infectious and Tropical Diseases


Centre for Evaluation
TB Centre


I teach epidemiology, HIV medicine, TB and clinical tropical medicine, particularly to students on MSc Tropical Medicine and International Health, and the LSHTM Diplomas in Tropical Medicine and Hygiene (in London and in East Africa).


My main research interest is improving care for people with HIV in developing countries, and preventing TB. Major projects include a cluster-randomised trial investigating a point-of-care TB test and treat algorithm for people with advanced HIV disease in South Africa; evaluation of South African national roll-out of Xpert MTB/RIF, a new TB diagnostic test replacing smear microscopy; investigation of how best to use Xpert MTB/RIF among people attending clinics for HIV care; linkage to care after a rifampicin-resistant Xpert MTB/RIF result in South Africa; and a trial comparing a single round of weekly isoniazid/rifapentine to periodic treatment. In collaboration with colleagues in South Africa, I have been involved with the design, implementation and evaluation of an HIV care programme in workplace and community settings.

I lead a programme of tuberculosis research at the Africa Health Research Institute, KwaZulu-Natal, South Africa.

I supervise research degree students working on use of Xpert MTB/RIF in South Africa and Botswana; determinants of TB infection among young people in South Africa;  pathways to TB care in Ghana; and the natural history of TB disease.

Research Area
Clinical care
Clinical trials
Implementation research
Randomised controlled trials
Operational research
Disease and Health Conditions
Infectious disease
United Kingdom
South Africa
Europe & Central Asia (all income levels)
Sub-Saharan Africa (all income levels)

Selected Publications

Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.
Grant AD; Charalambous S; Tlali M; Karat AS; Dorman SE; Hoffmann CJ; Johnson S; Vassall A; Churchyard GJ; Fielding KL
The Lancet HIV
Performance of verbal autopsy methods in estimating HIV-associated mortality among adults in South Africa.
Karat AS; Maraba N; Tlali M; Charalambous S; Chihota VN; Churchyard GJ; Fielding KL; Hanifa Y; Johnson S; McCarthy KM
BMJ global health
Cost of point-of-care lateral flow urine lipoarabinomannan antigen testing in HIV-positive adults in South Africa.
Mukora R; Tlali M; Monkwe S; Charalambous S; Karat AS; Fielding KL; Grant AD; Vassall A
The international journal of tuberculosis and lung disease
Measuring income for catastrophic cost estimates: Limitations and policy implications of current approaches.
Sweeney S; Mukora R; Candfield S; Guinness L; Grant AD; Vassall A
Social science & medicine (1982)
Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation.
Vassall A; Siapka M; Foster N; Cunnama L; Ramma L; Fielding K; McCarthy K; Churchyard G; Grant A; Sinanovic E
The Lancet Global health
Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models.
Houben RMGJ; Menzies NA; Sumner T; Huynh GH; Arinaminpathy N; Goldhaber-Fiebert JD; Lin H-H; Wu C-Y; Mandal S; Pandey S
The Lancet Global health
Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF.
Churchyard GJ; Stevens WS; Mametja LD; McCarthy KM; Chihota V; Nicol MP; Erasmus LK; Ndjeka NO; Mvusi L; Vassall A
The Lancet Global health
A trial of mass isoniazid preventive therapy for tuberculosis control.
Churchyard GJ; Fielding KL; Lewis JJ; Coetzee L; Corbett EL; Godfrey-Faussett P; Hayes RJ; Chaisson RE; Grant AD; Thibela TB Study Team
The New England journal of medicine
Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings.
Houben RMGJ; Sumner T; Grant AD; White RG
Proceedings of the National Academy of Sciences of the United States of America
See more Publications